<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04617470</url>
  </required_header>
  <id_info>
    <org_study_id>2487</org_study_id>
    <nct_id>NCT04617470</nct_id>
  </id_info>
  <brief_title>Niraparib as Maintenance Treatment in Platinum Responsive Ovarian Cancer Patients: a Real Life Study</brief_title>
  <acronym>MITO 34</acronym>
  <official_title>Niraparib as Maintenance Treatment in Platinum Responsive Ovarian Cancer Patients: a Real Life Study by MITO Group</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational phase IV study evaluating Niraparib as maintenance treatment in&#xD;
      patients with platinum sensitive, platinum responsive, recurrent ovarian cancer in a real&#xD;
      life setting.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an observational phase IV study evaluating Niraparib as maintenance treatment in&#xD;
      patients with platinum sensitive, platinum responsive, recurrent ovarian cancer in a real&#xD;
      life setting. Will be enrolled all patients who have been part of the Italian Compassionate&#xD;
      Use Program (CUP) prior to participating in this study. Once the CUP will be closed the trial&#xD;
      will continue with th prospective collection of data of patients treated with Niraparib&#xD;
      according to the label for 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 8, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>up to two years</time_frame>
    <description>To compare PFS of patients with advanced, platinum sensitive ovarian cancer treated with Niraparib as maintenance treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TFST</measure>
    <time_frame>up to two years</time_frame>
    <description>Time to first subsequent therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TSST</measure>
    <time_frame>up to two years</time_frame>
    <description>Time to second subsequent therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>up to two years</time_frame>
    <description>Overall Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>up to two years</time_frame>
    <description>Overall Response Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>up to two years</time_frame>
    <description>Toxicity will be evaluated by NCI CTCAE V 4.03</description>
  </secondary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Ovarian Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with platinum-sensitive, relapsed, high-grade serous epithelial ovarian, fallopian&#xD;
        tube, or primary peritoneal cancer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients that received niraparib as monotherapy for the maintenance treatment of&#xD;
             platinum-sensitive, relapsed, high-grade serous epithelial ovarian, fallopian tube, or&#xD;
             primary peritoneal cancer after response (complete or partial) to platinum-based&#xD;
             chemotherapy as part of the CUP, regardless of whether the patient is receiving&#xD;
             niraparib at the time of enrolment;&#xD;
&#xD;
          -  patients with high grade serous ovarian cancer treated with Niraparib according to the&#xD;
             label will be included;&#xD;
&#xD;
          -  patients able to understand the study procedures and that agree to participate in the&#xD;
             study by providing written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        No exclusion criteria&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Domenica Lorusso, MD</last_name>
    <phone>0630158545</phone>
    <phone_ext>0630158545</phone_ext>
    <email>domenica.lorusso@policlinicogemelli.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Serena Giolitto, MSc</last_name>
    <phone>0630158545</phone>
    <phone_ext>0630158545</phone_ext>
    <email>serena.giolitto@policlinicogemelli.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Domenica Lorusso, MD</last_name>
      <phone>0630158545</phone>
      <phone_ext>0630158545</phone_ext>
      <email>domenica.lorusso@policlinicogemelli.it</email>
    </contact>
    <contact_backup>
      <last_name>Serena Giolitto, MSc</last_name>
      <phone>0630158545</phone>
      <phone_ext>0630158545</phone_ext>
      <email>serena.giolitto@policlinicogemelli.it</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 5, 2020</study_first_submitted>
  <study_first_submitted_qc>November 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2020</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

